Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
|
|
Phio Pharmaceuticals Corp. (RXII)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update MARLBOROUGH, Mass., August 10, 2023—Phio Pharmaceuticals Corp. , a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2023 and provided a business update. “Following FDA clearance of our IND for PH-762, we are moving forward with plans for a clinical trial for stages one, two and four of cutaneous squamous cell , stage four melanoma and Merkel cell,” said Robert Bitterman, President and CEO. The initial multi-center, dose-escalating, Phase 1b clinical trial is designed to evaluate the safety and tolerability of neo..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 2,134 $ 1,586 General and administrative 1,468 1,054 Total operating expenses 3,602 2,640 Operating loss Total other expense, net – Net loss $ $ Net loss per common share: Basic and diluted $ $ Weighted average number of common shares outstanding: Basic and diluted 1,142,213 1,130,344 4 PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS" |
|
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 2,807 $ 1,256 $ 7,091 $ 3,253 General and administrative 932 1,050 2,970 3,078 Total operating expenses 3,739 2,306 10,061 6,331 Operating loss Total other income 225 Net loss $ $ $ $ Net loss per share: Basic and diluted $ $ $ $ Weight average shares outstanding: Basic and diluted 13,534,560 5,780,386 12,593,569 4,181,862 4 PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS" |
|
| 08/12/2021 |
8-K
| Quarterly results |
| 11/10/2020 |
8-K
| Quarterly results |
| 08/12/2020 |
8-K
| Quarterly results |
| 05/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/12/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Quarterly results|
Docs:
|
"For the Three For the Three Months Ended Months Ended March 31, 2019 March 31, 2018 Revenues $ 21 $ 23 Operating expenses: Research and development 1,089 1,361 General and administrative 1,078 901 Total operating expenses 2,167 2,262 Operating loss Total other income, net 27 – Net loss $ $ Net loss per share: Basic and diluted $ $ Weighted average shares: Basic and diluted 20,419,440 2,494,464 3 PHIO PHARMACEUTICALS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS" |
|
| 03/27/2019 |
8-K
| Quarterly results |
| 11/14/2018 |
8-K
| Quarterly results |
| 08/14/2018 |
8-K
| Quarterly results|
Docs:
|
"For the Three Months Ended For the Three Months Ended For the Six Months Ended For the Six Months Ended June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017 Revenues $ 58 $ – $ 81 $ – Operating expenses: Research and development 1,183 1,329 2,544 2,676 Acquired in-process research and development – 85 – 4,696 General and administrative 774 1,100 1,675 2,223 Total operating expenses 1,957 2,514 4,219 9,595 Operating loss Total other expense, net – – Loss before income taxes Income tax benefit – – – 1,621 Net loss $ $ $ $ Net loss per share: Basic and diluted $ $ $ $ Weighted average shares: Basic and diluted 4,102,423 2,238,836 3,302,885 2,148,477 4 RXi PHARMACEUTICALS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS" |
|
| 05/10/2018 |
8-K
| Quarterly results |
| 03/26/2018 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results |
| 08/10/2017 |
8-K
| Quarterly results |
| 05/11/2017 |
8-K
| Form 8-K - Current report |
| 03/30/2017 |
8-K
| Form 8-K - Current report |
| 11/10/2016 |
8-K
| Form 8-K - Current report |
| 08/11/2016 |
8-K
| Quarterly results |
| 05/12/2016 |
8-K
| Form 8-K - Current report |
| 03/30/2016 |
8-K
| Quarterly results|
Docs:
|
"RXi Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Recent Corporate Highlights MARLBOROUGH, Mass., March 30, 2016 /PRNewswire/ — RXi Pharmaceuticals Corporation , a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today reported its financial results for the fourth quarter and year ended December 31, 2015, and provided a business update. “During the last quarter of 2015, RXi advanced its pipeline with the initiation of three clinical trials and the selection of two self-delivering RNAi compounds for cosmetic product development, all while staying within the financial projections we have provided in the course of 2015,” said Dr. Geert Cauwenbergh, President and CEO of..." |
|
| 11/12/2015 |
8-K
| Quarterly results|
Docs:
|
"RXi Pharmaceuticals Reports Third Quarter 2015 Financial Results and Business Highlights MARLBOROUGH, Mass./PRNewswire/November 12, 2015 - RXi Pharmaceuticals Corporation , a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology, today reported its financial results for the quarter ended September 30, 2015 and provided a business update. “Since the beginning of Q3 of this year, RXi has made great progress on many fronts,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, “The Company achieved important value inflection events, announced positive clinical data results with RXI-109 for the treatment of hypertrophic scars, the activation of an IND for our ophthalmology prog..." |
|
| 08/12/2015 |
8-K
| Quarterly results|
Docs:
|
"RXi Pharmaceuticals Reports Second Quarter 2015 Financial Results and Business Highlights MARLBOROUGH, Mass./PRNewswire/August 12, 2015 - RXi Pharmaceuticals Corporation , a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology, today reported its financial results for the quarter ended June 30, 2015 and provided a business update. “In the second quarter, RXi reached a major milestone in our shareholder structure with the elimination of the preferred shares and their associated dilutive quarterly dividend. In addition, several investment funds became new shareholders in our recently completed financing,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added, “This financing provid..." |
|
| 05/13/2015 |
8-K
| Quarterly results |
| 03/30/2015 |
8-K
| Quarterly results |
|
|